scholarly journals Leg heat therapy improves perceived physical function but does not enhance walking capacity or vascular function in patients with peripheral artery disease

2020 ◽  
Vol 129 (6) ◽  
pp. 1279-1289
Author(s):  
Jacob C. Monroe ◽  
Chen Lin ◽  
Susan M. Perkins ◽  
Yan Han ◽  
Brett J. Wong ◽  
...  
Keyword(s):  
Physical Function ◽  
Peripheral Artery Disease ◽  
Vascular Function ◽  
Controlled Study ◽  
Peripheral Artery ◽  
Walking Capacity ◽  
Heat Therapy ◽  
Walking Performance ◽  
Artery Disease ◽  
Potent Vasoconstrictor

This is the first sham-controlled study to investigate the effects of leg heat therapy (HT) on walking performance, vascular function, and quality of life in patients with peripheral artery disease (PAD). Adherence to HT was high, and the treatment was well tolerated. Our findings revealed that HT applied with water-circulating trousers evokes a clinically meaningful increase in perceived physical function and reduces the serum concentration of the potent vasoconstrictor endothelin-1 in patients with PAD.

scholarly journals Dietary Nitrate Intake Improves Vascular Function And Walking Capacity In Patients With Peripheral Artery Disease

2020 ◽  
Vol 52 (7S) ◽  
pp. 894-895
Author(s):  
TeSean K. Wooden ◽  
Elizabeth J. Pekas ◽  
Ronald J. Headid ◽  
Won-Mok Son ◽  
Song-Young Park
Keyword(s):  
Peripheral Artery Disease ◽  
Vascular Function ◽  
Peripheral Artery ◽  
Dietary Nitrate ◽  
Nitrate Intake ◽  
Walking Capacity ◽  
Artery Disease

Abstract 11: Effects of Canakinumab in Patients With Peripheral Artery Disease

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Kerry S Russell ◽  
Denise Yates ◽  
Andrea Feller ◽  
Tianke Wang ◽  
Ping Chen ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Vascular Function ◽  
Cardiovascular Events ◽  
Ankle Brachial Index ◽  
Unmet Need ◽  
Walking Distance ◽  
Plaque Progression ◽  
Peripheral Artery ◽  
Plaque Volume ◽  
Artery Disease

Background: Peripheral artery disease (PAD) affects 8.5 million people in the US. PAD patients are at high risk for cardiovascular events, and their quality of life is often significantly impaired by decreased mobility. Interleukin-1β (IL-1β) may play an important role in this disease by promoting inflammatory responses that drive atherosclerotic plaque progression and impair vascular function. We sought to test whether interruption of IL-1β signaling would improve patient mobility and decrease plaque progression in the lower extremities. Methods: 38 patients (mean age 65; 71% male) with symptomatic PAD (confirmed by ankle-brachial index) were randomized 1:1 to receive Canakinumab (150 mg subcutaneously) or placebo monthly for up to 12 months. Plaque volume in the superficial femoral artery (SFA) was assessed serially using 3.0T MRI. Mobility was assessed serially using the 6-minute walk test (maximum and pain-free walking distance). Results: Canakinumab was safe and well-tolerated. 12 patients discontinued (8 placebo, 4 Canakinumab). MRI data (from 31 patients at 3 months; 21 patients at 12 months) showed no evidence of plaque progression in the SFA at either time point in placebo-treated patients; nor was there a change in plaque volume in the Canakinumab-treated group. There was a serial and significant improvement in placebo-adjusted maximum and pain-free walking distance observed as early as 3 months after treatment with Canakinumab (58-meter improvement over placebo in pain-free distance at 3 months, P=0.01). Two placebo-treated patients required peripheral vascular interventions due to progression of disease; however, no Canakinumab-treated patients required revascularization during the study. Canakinumab decreased markers of systemic inflammation (IL-6 and hsCRP). Conclusions: Treatment with Canakinumab may improve maximum and pain-free walk distance in patients with symptomatic PAD. In conjunction with results soon to be reported for the CANTOS trial of Canakinumab for secondary prevention of cardiovascular events, additional studies may provide support that inhibition of IL-1β signaling can improve symptoms and function in this patient population with high unmet need.

scholarly journals Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease

JAMA ◽  
2018 ◽  
Vol 319 (16) ◽  
pp. 1665 ◽  
Author(s):  
Mary M. McDermott ◽  
Bonnie Spring ◽  
Jeffrey S. Berger ◽  
Diane Treat-Jacobson ◽  
Michael S. Conte ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Exercise Intervention ◽  
Wearable Technology ◽  
Peripheral Artery ◽  
Home Based ◽  
Walking Performance ◽  
Artery Disease ◽  
Telephone Coaching

Mitochondrial DNA damage in calf skeletal muscle and walking performance in people with peripheral artery disease

2020 ◽  
Vol 160 ◽  
pp. 680-689 ◽  
Author(s):  
Sunil K. Saini ◽  
Mary M. McDermott ◽  
Anna Picca ◽  
Lingyu Li ◽  
Stephanie E. Wohlgemuth ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Dna Damage ◽  
Mitochondrial Dna ◽  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Mitochondrial Dna Damage ◽  
Walking Performance ◽  
Artery Disease

Effects of Clustered Comorbid Conditions on Walking Capacity in Patients with Peripheral Artery Disease

2014 ◽  
Vol 28 (2) ◽  
pp. 279-283 ◽  
Author(s):  
Breno Quintella Farah ◽  
Raphael Mendes Ritti-Dias ◽  
Gabriel Grizzo Cucato ◽  
Marcel da Rocha Chehuen ◽  
João Paulo dos Anjos Souza Barbosa ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Comorbid Conditions ◽  
Peripheral Artery ◽  
Walking Capacity ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document